Skip to main content

Find Clinical Trials

Home
Conditions
Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin

Clinical trial condition

Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin

Explore clinical trials studying Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin trial results

Active, Not Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

NCT05271318

Conditions: Adenoviridae Infections, DNA Virus Infections, Infections, +10 more
Locations: Mayo Clinic Rochester, Minnesota, United States

Northwell Heatlh/Lenox Hill Hospital New York, United States

Docrates Cancer Center Helsinki, Finland

View Trial Details